
Danish pharmaceutical company ALK has licensed Singapore-based Zuellig Pharma to launch ALK’s emergency allergy treatment neffy in six Southeast Asian countries: Singapore, Thailand, the Philippines, Malaysia, Indonesia and Vietnam.
The agreement was announced on 17 November 2026 as part of ALK’s third-quarter financial report. Under the partnership, Zuellig Pharma will sub-license neffy from ALK and purchase finished products for distribution in the region.
Neffy is an adrenaline nasal spray used for emergency treatment of severe allergic reactions, including anaphylaxis. Unlike conventional adrenaline auto-injectors, the medicine is administered without a needle.
According to ALK, the treatment could become available in the six countries within the next few years, subject to regulatory approval. The agreement also allows for potential expansion into additional markets.
ALK, headquartered in Hørsholm, Denmark, specialises in allergy treatments. The partnership forms part of its efforts to extend access to its products internationally.
Zuellig Pharma is a major healthcare distribution and commercialisation company operating across Asia.
Sources: ALK – Nine-month interim report, 17 November 2026 , ALK – Full financial report (PDF)

